Objective To investigate the change of interleukin-17 (IL-17) and interleukin-6 (IL-6) in the process of rats pulmonary fibrosis, and to observe the effection of this two factors on rats pulmonary fibrosis. Methods 72 healthy male Wistar rats were randomly divided into three groups: normal control group (group N), pulmonary fibrosis model group (group M) and dexamethasone treatment group (group T). Model group and treatment group received intra-tracheal instillation of 5 mg/kg bleomycin (BLM), preparation of pulmonary fibrosis. Normal control group received intra-tracheal instillation of saline instead. The next day treatment group injected dexamethasone (1 mg/kg) by intraperitoneal every other day. The control group and model group were injected with saline. The rats were killed on the 3rd, 7th, 14th and 28th day after modeling. Hold the lung tissue and embed in paraffin to observe the lung tissue pathological sectionl changes and determine the level of hydroxyproline in lung tissue. The levels of IL-17 and IL-6 in surem were measured by double antibody sandwich (ELISA). Results In model group, lung tissue biopsy showed the dynamic process of change from alveolitis to fibrosis gradually, and the level of hydroxyproline in lung tissue was higher than the control group and dexamethasone group. Levels of IL-17 and IL-6 in surem in the model group were significantly higher than the control group and treatment group at all time points. In model group and treatment group, IL-17 and IL-6 had peak on 7th day. Conclusion The high expression of IL-17 and IL-6 in lung fibrosis model group suggests that it may involves in the formation of pulmonary fibrosis.%目的 研究IL-17及IL-6在大鼠肺纤维化发生过程中的表达,以探讨其可能在大鼠肺纤维化发生发展过程中作用.方法 取健康雄性Wistar大鼠72只,随机分为正常对照组(N组)、肺纤维化模型组(M组)及地塞米松治疗组(T组).肺纤维化模型组和地塞米松治疗组向气管内灌注博来霉素(BLM)5 mg/kg,制备肺纤维化模型.正常对照组采用气管内灌注生理盐水替代.地塞米松治疗组于次日腹腔注射地塞米松注射液(1 mg/kg),隔日1次.正常对照组和肺纤维化模型组腹腔注射生理盐水.三组动物于造模后第3、7、14、28天分批处死.留取肺组织,石蜡包埋切片,观察其病理学改变并测定肺组织中羟脯氨酸含量.用双抗夹心酶联免疫吸附试验(ELISA)法检测血清中IL-17及IL-6的含量.结果 肺纤维化模型组肺组织病理切片表现为逐渐由肺泡炎至纤维化动态改变过程,肺组织内羟脯氨酸高于正常对照组和地塞米松治疗组.肺纤维化模型组血清IL-17水平、IL-6水平各时间点均明显高于正常对照组及地塞米松治疗组.肺纤维化模型组及地塞米松治疗组血清IL-17及IL-6水平于第7天达到峰值.结论 IL-17及IL-6在肺纤维化模型组的高表达,提示其可能参与肺纤维化形成过程.
展开▼
